Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
ADP-ribosylation factors (ARFs) play an important role in intracellular vesicular trafficking.
Showing 10 out of 42 products:
Human Polyclonal ARFGEF2 Primary Antibody for ICC, IF - ABIN4281377
Christis, Munro: The small G protein Arl1 directs the trans-Golgi-specific targeting of the Arf1 exchange factors BIG1 and BIG2. in The Journal of cell biology 2012
coordinated interactions between actin (through FlnA) and vesicle trafficking (through Big2-Arf) direct the assembly and disassembly of membrane protein complexes required for neuronal migration and neuroependymal integrity.
an early acting GEF (show ARHGEF2 Antibodies) (GBF1 (show PTGES2 Antibodies)) activates ARFs that mediate recruitment of late acting GEFs (BIG1 (show CNTN3 Antibodies)/2) to coordinate coating events within the pre-Golgi/Golgi/TGN (show TG Antibodies) continuum.
Big2 inhibition promotes Filamin A (show FLNA Antibodies) phosphorylation, thereby disrupting cell intrinsic neuronal migration.
Results indicate that murine BIG2 is essential for early embryonic development.
Both phospholipase D (show PLD Antibodies) activity and vesicular trafficking were required for effects of BIG1 (show CNTN3 Antibodies) and BIG2 on beta-catenin (show CTNNB1 Antibodies) activation. Levels of PKA-phosphorylated beta-catenin (show CTNNB1 Antibodies) S675 and beta-catenin (show CTNNB1 Antibodies) association with PKA, BIG1 (show CNTN3 Antibodies), and BIG2 were also diminished after BIG1 (show CNTN3 Antibodies)/BIG2 depletion.
Description of a novel ARFGEF2 mutation in five related patients presenting with West syndrome, microcephaly, periventricular heterotopia and thin corpus callosum.
The clinical phenotype associated with mutations in ARFGEF2 is relatively homogeneous in the families report.
Arf guanine nucleotide-exchange factors BIG1 and BIG2 regulate nonmuscle myosin IIA activity by anchoring myosin phosphatase complex.
an early acting GEF (show SLC2A4RG Antibodies) (GBF1 (show GBF1 Antibodies)) activates ARFs that mediate recruitment of late acting GEFs (BIG1 (show CNTN3 Antibodies)/2) to coordinate coating events within the pre-Golgi/Golgi/TGN (show TG Antibodies) continuum.
Brefeldin A-inhibited ADP-ribosylation factor activator BIG2 regulates cell migration via integrin beta1 cycling and actin remodeling.
Up-regulation of ARFGEF2 is associated with the Huntington's disease.
BIG1 (show CNTN3 Antibodies) and BIG2 have roles in endomembrane organization
BIG2 and Exo70 (show EXOC7 Antibodies) interact in trans-Golgi network and centrosomes, as well as in exocyst structures or complexes that move along microtubules to the plasma membrane.
ARFGEF2 mRNA was widely expressed in all cortical layers, especially in the neural precursors of the ventricular and subventricular zones during development, with persistent but diminished expression in adulthood.
ADP-ribosylation factors (ARFs) play an important role in intracellular vesicular trafficking. The protein encoded by this gene is involved in the activation of ARFs by accelerating replacement of bound GDP with GTP and is involved in Golgi transport. It contains a Sec7 domain, which may be responsible for its guanine-nucleotide exchange activity and also brefeldin A inhibition.
ADP-ribosylation factor guanine nucleotide-exchange factor 2 (brefeldin A-inhibited)
, cytohesin 1-like
, brefeldin A-inhibited GEP 2
, brefeldin A-inhibited guanine nucleotide-exchange protein 2
, Brefeldin A-inhibited guanine nucleotide-exchange factor 2